Conning Inc. Abb Vie Inc. Transaction History

Conning Inc.

$2.67 Billion
Q2 2024

A detailed history of Conning Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Conning Inc. holds 230,385 shares of ABBV stock, worth $44.6 Million. This represents 1.48% of its overall portfolio holdings.

Number of Shares

230,385

Previous 223,458 3.1%

Holding current value

$44.6 Million

Previous $40.7 Million 2.89%

% of portfolio

1.48%

Previous 1.39%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	BUY	$154.79 - $180.76 $1.07 Million - $1.25 Million	6,927 Added 3.1%	230,385 $39.5 Million
Q1 2024 Apr 26, 2024	SELL	$159.82 - $182.1 $3.08 Million - $3.51 Million	-19,288 Reduced 7.95%	223,458 $40.7 Million
Q4 2023 Jan 29, 2024	SELL	$137.6 - $154.97 $1.28 Million - $1.45 Million	-9,330 Reduced 3.7%	242,746 $37.6 Million
Q3 2023 Oct 26, 2023	SELL	$133.59 - $154.65 $2.46 Million - $2.85 Million	-18,421 Reduced 6.81%	252,076 $37.6 Million
Q2 2023 Jul 21, 2023	BUY	$132.51 - $164.9 $2.84 Million - $3.53 Million	21,436 Added 8.61%	270,497 $36.4 Million
Q1 2023 Apr 27, 2023	BUY	$144.61 - $166.54 $723,483 - $833,199	5,003 Added 2.05%	249,061 $39.7 Million
Q4 2022 Feb 07, 2023	SELL	$138.31 - $165.87 $3.99 Million - $4.79 Million	-28,851 Reduced 10.57%	244,058 $39.5 Million
Q3 2022 Oct 28, 2022	SELL	$134.21 - $153.93 $5.34 Million - $6.13 Million	-39,804 Reduced 12.73%	272,909 $36.6 Million
Q2 2022 Jul 20, 2022	BUY	$137.62 - $174.96 $40.5 Million - $51.5 Million	294,343 Added 1602.3%	312,713 $47.9 Million
Q1 2022 May 02, 2022	BUY	$131.98 - $163.75 $9,502 - $11,790	72 Added 0.39%	18,370 $2.98 Million
Q4 2021 Jan 27, 2022	SELL	$107.43 - $135.93 $154,699 - $195,739	-1,440 Reduced 7.3%	18,298 $2.48 Million
Q3 2021 Nov 05, 2021	SELL	$106.4 - $120.78 $219,928 - $249,652	-2,067 Reduced 9.48%	19,738 $2.13 Million
Q2 2021 Jul 29, 2021	SELL	$105.21 - $117.21 $125,725 - $140,065	-1,195 Reduced 5.2%	21,805 $2.46 Million
Q1 2021 Apr 23, 2021	SELL	$102.3 - $112.62 $213,807 - $235,375	-2,090 Reduced 8.33%	23,000 $2.49 Million
Q4 2020 Jan 28, 2021	SELL	$80.49 - $108.67 $67,611 - $91,282	-840 Reduced 3.24%	25,090 $2.69 Million
Q3 2020 Oct 21, 2020	BUY	$85.91 - $100.83 $26,632 - $31,257	310 Added 1.21%	25,930 $2.27 Million
Q2 2020 Aug 07, 2020	BUY	$73.37 - $98.18 $199,346 - $266,755	2,717 Added 11.86%	25,620 $2.52 Million
Q1 2020 Apr 29, 2020	SELL	$64.5 - $97.79 $17,673 - $26,794	-274 Reduced 1.18%	22,903 $1.75 Million
Q4 2019 Jan 29, 2020	SELL	$72.13 - $90.25 $4.98 Million - $6.23 Million	-69,072 Reduced 74.88%	23,177 $2.05 Million
Q3 2019 Oct 30, 2019	SELL	$62.98 - $75.72 $4,408 - $5,300	-70 Reduced 0.08%	92,249 $6.99 Million
Q2 2019 Jul 25, 2019	SELL	$65.7 - $83.98 $31.2 Million - $39.9 Million	-474,549 Reduced 83.71%	92,319 $6.71 Million
Q1 2019 Apr 22, 2019	BUY	$77.14 - $90.79 $5.5 Million - $6.47 Million	71,309 Added 14.39%	566,868 $45.7 Million
Q4 2018 Jan 29, 2019	SELL	$77.85 - $96.01 $648,724 - $800,051	-8,333 Reduced 1.65%	495,559 $45.7 Million
Q3 2018 Oct 26, 2018	BUY	$88.91 - $98.84 $3.6 Million - $4 Million	40,481 Added 8.74%	503,892 $47.7 Million
Q2 2018 Jul 25, 2018	BUY	$89.78 - $106.23 $6.28 Million - $7.43 Million	69,982 Added 17.79%	463,411 $42.9 Million
Q1 2018 May 04, 2018	BUY	$92.01 - $123.21 $22.8 Million - $30.5 Million	247,545 Added 169.69%	393,429 $37.2 Million
Q4 2017 Jan 30, 2018	BUY	$89.56 - $98.21 $8.34 Million - $9.14 Million	93,090 Added 176.33%	145,884 $14.1 Million
Q3 2017 Oct 20, 2017	BUY	$69.85 - $89.22 $3.69 Million - $4.71 Million	52,794	52,794 $4.69 Million

Others Institutions Holding ABBV

# of Institutions

3,689

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $342B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.

Account